Small RNA interference-mediated gene silencing of heparanase abolishes the invasion, metastasis and angiogenesis of gastric cancer cells

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Zheng, Liduan ^a   Jiang, Guosong ^a   Mei, Hong ^a   Pu, Jiarui ^a   Dong, Jihua ^a   Hou, Xiaohua ^a   Tong, Qiangsong ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARANASE; SMALL INTERFERING RNA; BETA GLUCURONIDASE;

ANGIOGENESIS; ARTICLE; CANCER CELL; CANCER INVASION; CELL ADHESION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; GENE EXPRESSION; GENE FUNCTION; GENE REPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; METASTASIS; NUCLEOTIDE SEQUENCE; REAL TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNA SYNTHESIS; STOMACH CANCER; WESTERN BLOTTING; BIOSYNTHESIS; CELL GROWTH; CELL MOTION; DRUG ANTAGONISM; ENZYMOLOGY; GENETIC TRANSFECTION; GENETICS; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PHYSIOLOGY; STOMACH TUMOR; TUMOR CELL LINE; VASCULARIZATION;

CELL ADHESION; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CELL MOVEMENT; GENE SILENCING; GLUCURONIDASE; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; RNA, SMALL INTERFERING; STOMACH NEOPLASMS; TRANSFECTION;

EID: 77949508295     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-33     Document Type: Article

References (50)

1. Terry MB, Gaudet MM, Gammon MD. The epidemiology of gastric cancer. Semin Radiat Oncol 2002, 12(2):111-127. 10.1053/srao.30814, 11979413.
2. Li C, Oh SJ, Kim S, Hyung WJ, Yan M, Zhu ZG, Noh SH. Risk factors of survival and surgical treatment for advanced gastric cancer with large tumor size. J Gastrointest Surg 2009, 13(5):881-885. 10.1007/s11605-009-0800-3, 19184612.
3. Liotta LA, Stetler-Stevenson WG. Tumor invasion and metastasis: an imbalance of positive and negative regulation. Cancer Res 1991, 51(18 Suppl):5054s-5059s.
4. Wu CY, Wu MS, Chiang EP, Chen YJ, Chen CJ, Chi NH, Shih YT, Chen GH, Lin JT. Plasma matrix metalloproteinase-9 level is better than serum matrix metalloproteinase-9 level to predict gastric cancer evolution. Clin Cancer Res 2007, 13(7):2054-2060. 10.1158/1078-0432.CCR-06-2299, 17404086.
5. Kubben FJGM, Sier CFM, van Duijn W, Griffioen G, Hanemaaijer R, Velde CJH, van Krieken JHJM, Lamers CBHW, Verspaget HW. Matrix metalloproteinase-2 is a consistent prognostic factor in gastric cancer. Br J Cancer 2006, 94(7):1035-1040. 10.1038/sj.bjc.6603041, 2361233, 16538217.
6. Deng H, Guo RF, Li WM, Zhao M, Lu YY. Matrix metalloproteinase 11 depletion inhibits cell proliferation in gastric cancer cells. Biochem Biophys Res Commun 2005, 326(2):274-281. 10.1016/j.bbrc.2004.11.027, 15582574.
7. Kaneko T, Konno H, Baba M, Tanaka T, Nakamura S. Urokinase-type plasminogen activator expression correlates with tumor angiogenesis and poor outcome in gastric cancer. Cancer Sci 2003, 94(1):43-49. 10.1111/j.1349-7006.2003.tb01350.x, 12708473.
8. Vlodavsky I, Ilan N, Naggi A, Casu B. Heparanase: structure, biological functions, and inhibition by heparin-derived mimetics of heparan sulfate. Curr Pharm Des 2007, 13(20):2057-2073. 10.2174/138161207781039742, 17627539.
9. Nakajima M, Irimura T, Di Ferrante N, Nicolson GL. Metastatic melanoma cell heparanase. Characterization of heparan sulfate degradation fragments produced by B16 melanoma endoglucuronidase. J Biol Chem 1984, 259(4):2283-2290.
10. Nasser NJ. Heparanase involvement in physiology and disease. Cell Mol Life Sci 2008, 65(11):1706-1715. 10.1007/s00018-008-7584-6, 18425416.
11. Ikeguchi M, Fukuda K, Yamaguchi K, Kondo A, Tsujitani S, Kaibara N. Quantitative analysis of heparanase gene expression in esophageal squamous cell carcinoma. Ann Surg Oncol 2003, 10(3):297-304. 10.1245/ASO.2003.05.022, 12679316.
12. Kim AW, Xu X, Hollinger EF, Gattuso P, Godellas CV, Prinz RA. Human heparanase-1 gene expression in pancreatic adenocarcinoma. J Gastrointestinal Surg 2003, 6(2):167-172.
13. Rivera RS, Nagatsuka H, Siar CH, Gunduz M, Tsujigiwa H, Han PP, Katase N, Tamamura R, Ng KH, Naomoto Y, Nakajima M, Nagai N. Heparanase and vascular endothelial growth factor expression in the progression of oral mucosal melanoma. Oncol Rep 2008, 19(3):657-661.
14. Kazu G, Masa O, Sohe K, Mina T, Jian D, Yoji K, Moto N. Heparanase protein and gene expression in bladder cancer. J Urol 2001, 166(4):1286-1290. 10.1016/S0022-5347(05)65754-0, 11547059.
15. Stadlmann S, Moser PL, Pollheimer J, Steiner P, Krugmann J, Dirnhofer S, Mikuz G, Margreiter R, Amberger A. Heparanase-1 gene expression in normal, hyperplastic and neoplastic prostatic tissue. Eur J Cancer 2003, 39(15):2229-2233. 10.1016/S0959-8049(03)00457-X, 14522383.
16. Vlodavsky I, Ilan N, Nadir Y, Brenner B, Katz BZ, Naggi A, Torri G, Casu B, Sasisekharan R. Heparanase, heparin and the coagulation system in cancer progression. Thromb Res 2007, 120(Supplement 2):S112-S120. 10.1016/S0049-3848(07)70139-1, 18023704.
17. Wang Z, Xu H, Jiang L, Zhou X, Lu C, Zhang X. Positive association of heparanase expression with tumor invasion and lymphatic metastasis in gastric carcinoma. Mod Pathol 2004, 18(2):205-211.
18. Takaoka M, Naomoto Y, Ohkawa T, Uetsuka H, Shirakawa Y, Uno F, Fujiwara T, Gunduz M, Nagatsuka H, Nakajima M, Tanaka N, Haisa M. Heparanase expression correlates with invasion and poor prognosis in gastric cancers. Lab Invest 2003, 83(5):613-622.
19. Bar-Ner M, Eldor A, Wasserman L, Matzner Y, Cohen IR, Fuks Z, Vlodavsky I. Inhibition of heparanase-mediated degradation of extracellular matrix heparan sulfate by non-anticoagulant heparin species. Blood 1987, 70(2):551-557.
20. Nakajima M, DeChavigny A, Johnson CE, Hamada J, Stein CA, Nicolson GL. Suramin. A potent inhibitor of melanoma heparanase and invasion. J Biol Chem 1991, 266(15):9661-9666.
21. Simizu S, Ishida K, Wierzba MK, Osada H. Secretion of heparanase protein is regulated by glycosylation in human tumor cell lines. J Biol Chem 2004, 279(4):2697-2703. 10.1074/jbc.M300541200, 14573609.
22. Levidiotis V, Freeman C, Punler M, Martinello P, Creese B, Ferro V, Vlag J, Berden JHM, Parish CR, Power DA. A Synthetic Heparanase Inhibitor Reduces Proteinuria in Passive Heymann Nephritis. J Am Soc Nephrol 2004, 15(11):2882-2892. 10.1097/01.ASN.0000142426.55612.6D, 15504941.
23. Hua-Quan M, Hu L, Navarro E, Kussie P, Zhenping Z. Development of heparanase inhibitors for anti-cancer therapy. Curr Med Chem 2006, 13(18):2101-2111. 10.2174/092986706777935230, 16918340.
24. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001, 411(6836):494-498. 10.1038/35078107, 11373684.
25. Izquierdo M. Short interfering RNAs as a tool for cancer gene therapy. Cancer Gene Ther 2004, 12(3):217-227.
26. Mathews DH, Sabina J, Zuker M, Turner DH. Expanded sequence dependence of thermodynamic parameters improves prediction of RNA secondary structure. J Mol Biol 1999, 288(5):911-940. 10.1006/jmbi.1999.2700, 10329189.
27. Nicosia RF, Ottinetti A. Growth of microvessels in serum-free matrix culture of rat aorta. A quantitative assay of angiogenesis in vitro. Lab Invest 1990, 63(1):115-122.
28. Cohen I, Pappo O, Elkin M, San T, Bar-Shavit R, Hazan R, Peretz T, Vlodavsky I, Abramovitch R. Heparanase promotes growth, angiogenesis and survival of primary breast tumors. Int J Cancer 2006, 118(7):1609-1617. 10.1002/ijc.21552, 16217746.
29. Elkin M, Ilan N, Ishai-Michaeli R, Friedmann Y, Papo O, Pecker I, Vlodavsky I. Heparanase as mediator of angiogenesis: mode of action. FASEB J 2001, 15(9):1661-1663.
30. Vlodavsky I, Friedmann Y. Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis. J Clin Invest 2001, 108(3):341-347. 209369, 11489924.
31. Boyd D. Invasion and metastasis. Cancer Metastasis Rev 1996, 15(1):77-89. 10.1007/BF00049488, 8842480.
32. Vlodavsky I, Friedmann Y, Elkin M, Aingorn H, Atzmon R, Ishai-Michaeli R, Bitan M, Pappo O, Peretz T, Michal I, Spector L, Pecker I. Mammalian heparanase: Gene cloning, expression and function in tumor progression and metastasis. Nat Med 1999, 5(7):793-802. 10.1038/10518, 10395325.
33. Hulett MD, Freeman C, Hamdorf BJ, Baker RT, Harris MJ, Parish CR. Cloning of mammalian heparanase, an important enzyme in tumor invasion and metastasis. Nat Med 1999, 5(7):803-809. 10.1038/10525, 10395326.
34. McKenzie E, Tyson K, Stamps A, Smith P, Turner P, Barry R, Hircock M, Patel S, Barry E, Stubberfield C, Terrett J, Page M. Cloning and expression profiling of hpa2, a novel mammalian heparanase family member. Biochem Biophys Res Commun 2000, 276(3):1170-1177. 10.1006/bbrc.2000.3586, 11027606.
35. Bar-Sela G, Kaplan-Cohen V, Ilan N, Vlodavsky I, Ben-Izhak O. Heparanase expression in nasopharyngeal carcinoma inversely correlates with patient survival. Histopathology 2006, 49(2):188-193. 10.1111/j.1365-2559.2006.02469.x, 16879396.
36. Ikeguchi M, Hirooka Y, Kaibara N. Heparanase gene expression and its correlation with spontaneous apoptosis in hepatocytes of cirrhotic liver and carcinoma. Eur J Cancer 2003, 39(1):86-90. 10.1016/S0959-8049(02)00558-0, 12504663.
37. Koliopanos A, Friess H, Kleeff J, Shi X, Liao Q, Pecker I, Vlodavsky I, Zimmermann A, Buchler MW. Heparanase expression in primary and metastatic pancreatic cancer. Cancer Res 2001, 61(12):4655-4659.
38. Edovitsky E, Elkin M, Zcharia E, Peretz T, Vlodavsky I. Heparanase gene silencing, tumor invasiveness, angiogenesis, and metastasis. J Natl Cancer Inst 2004, 96(16):1219-1230.
39. Miao HQ, Elkin M, Aingorn E, Ishai-Michaeli R, Stein CA, Vlodavsky I. Inhibition of heparanase activity and tumor metastasis by laminarin sulfate and synthetic phosphorothioate oligodeoxynucleotides. Int J Cancer 1999, 83(3):424-431. 10.1002/(SICI)1097-0215(19991029)83:3<424::AID-IJC20>3.0.CO;2-L, 10495437.
40. Karoli T, Liu L, Fairweather JK, Hammond E, Li CP, Cochran S, Bergefall K, Trybala E, Addison RS, Ferro V. Synthesis, biological activity, and preliminary pharmacokinetic evaluation of analogues of a phosphosulfomannan angiogenesis inhibitor (PI-88). J Med Chem 2005, 48(26):8229-8236. 10.1021/jm050618p, 16366604.
41. Khvorova A, Reynolds A, Jayasena SD. Functional siRNAs and miRNAs exhibit strand bias. Cell 2003, 115(2):209-216. 10.1016/S0092-8674(03)00801-8, 14567918.
42. Schwarz DS, Hutvágner G, Du T, Xu Z, Aronin N, Zamore PD. Asymmetry in the assembly of the RNAi enzyme complex. Cell 2003, 115(2):199-208. 10.1016/S0092-8674(03)00759-1, 14567917.
43. Kretschmer-Kazemi Far R, Sczakiel G. The activity of siRNA in mammalian cells is related to structural target accessibility: a comparison with antisense oligonucleotides. Nucl Acids Res 2003, 31(15):4417-4424. 10.1093/nar/gkg649, 169945, 12888501.
44. Luo KQ, Chang DC. The gene-silencing efficiency of siRNA is strongly dependent on the local structure of mRNA at the targeted region. Biochem Biophys Res Commun 2004, 318(1):303-310. 10.1016/j.bbrc.2004.04.027, 15110788.
45. Heale BSE, Soifer HS, Bowers C, Rossi JJ. siRNA target site secondary structure predictions using local stable substructures. Nucl Acids Res 2005, 33(3):e30. 10.1093/nar/gni026, 549425, 15722476.
46. Patzel V. In silico selection of active siRNA. Drug Discov Today 2007, 12(3-4):139-148. 10.1016/j.drudis.2006.11.015, 17275734.
47. Schubert S, Grünweller A, Erdmann VA, Kurreck J. Local RNA target structure influences siRNA efficacy: systematic analysis of intentionally designed binding regions. J Mol Biol 2005, 348(4):883-893. 10.1016/j.jmb.2005.03.011, 15843020.
48. Holen T, Amarzguioui M, Wiiger MT, Babaie E, Prydz H. Positional effects of short interfering RNAs targeting the human coagulation trigger tissue factor. Nucl Acids Res 2002, 30(8):1757-1766. 10.1093/nar/30.8.1757, 113209, 11937629.
49. Vlodavsky I, Goldshmidt O, Zcharia E, Atzmon R, Rangini-Guatta Z, Elkin M, Peretz T, Friedmann Y. Mammalian heparanase: involvement in cancer metastasis, angiogenesis and normal development. Semin Cancer Biol 2002, 12(2):121-129. 10.1006/scbi.2001.0420, 12027584.
50. Liu T, Yin JQ, Shang B, Min Z, He H, Jiang J, Chen F, Zhen Y, Shao R. Silencing of hdm2 oncogene by siRNA inhibits p53-dependent human breast cancer. Cancer Gene Ther 2004, 11(11):748-756. 10.1038/sj.cgt.7700753, 15375377.